Use of chemotherapy for patients with estrogen receptor (ER)-positive breast cancer has been a conflicting issue. Recent studies have identified predictive markers allowing identification of poor-prognosis ER-positive breast cancers in need of more aggressive bihada-josei.info by: Sep 20, · Hormone receptor-positive (or hormone-positive) breast cancer cells have either estrogen (ER) or progesterone (PR) receptors or both. These breast cancers can be treated with hormone therapy drugs that lower estrogen levels or block estrogen receptors.
Sep 06, · If you have ER-positive breast cancer, your cancer cells grow in the presence of the hormone estrogen. Estrogen occurs naturally in the body. Estrogen occurs naturally in the bihada-josei.info: Ann Silberman. Optimization of adjuvant systemic therapy in women with early-stage hormone receptor-positive breast cancer includes the consideration of chemotherapy and ideal type and duration of anti-hormone bihada-josei.info: Ludimila L. Cavalcante.
Sep 15, · SERMs block the effects of estrogen in the breast tissue by attaching to the estrogen receptors in breast cells. Tamoxifen is the SERM most commonly used to treat breast cancer. Another SERM called Fareston (chemical name: toremifene) is sometimes used to treat advanced breast cancer in postmenopausal women. Aromatase inhibitors. Hormone therapy is also a treatment option for ER-positive breast cancer that has come back in the breast, chest wall, or nearby lymph nodes after treatment (also called a locoregional recurrence). Two SERMs are approved to treat metastatic breast cancer, tamoxifen and toremifene.